Abstract
In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Anti-Cancer Agents in Medicinal Chemistry
Title:Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Volume: 16 Issue: 11
Author(s): Gerd Ludwig, Marija Mojić, Mirna Bulatović, Sanja Mijatović, Danijela Maksimović-Ivanić, Dirk Steinborn and Goran N. Kaluđerović
Affiliation:
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Abstract: In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Export Options
About this article
Cite this article as:
Ludwig Gerd, Mojić Marija, Bulatović Mirna, Mijatović Sanja, Maksimović-Ivanić Danijela, Steinborn Dirk and Kaluđerović N. Goran, Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1871520615666151029100749
DOI https://dx.doi.org/10.2174/1871520615666151029100749 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor metastasis ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually all worldwide. The Global burden of cancer (GLOBOCAN) 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040.In the future , female breast cancer will be the most common cancer (11.7%) followed by ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumoural Expression of Connective Tissue Growth Factor (CTGF) Impacts on Survival in Patients Diagnosed with Hepatocellular Carcinoma (HCC)
Current Cancer Drug Targets Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Effect of Herbal Aphrodisiac, <i>Dioscorea Bulbifera</i> on Sperm Parameters, Serum Hormonal Levels and Testicular Histology of Wistar Rats
Current Traditional Medicine The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy
Current Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Retinoids as Therapeutic Agents: Today and Tomorrow
Mini-Reviews in Medicinal Chemistry Simplified Receptor Based Pharmacophore Approach to Retrieve Potent PTP-LAR Inhibitors Using Apoenzyme
Current Computer-Aided Drug Design A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry Radioactive Nanoparticles and their Main Applications: Recent Advances
Recent Patents on Nanotechnology Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Expression, Purification and Structural Characterization of Up-Regulated Gene 7 Encoded Protein
Protein & Peptide Letters Takotsubo Cardiomyopathy
Current Pharmaceutical Design Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design